Developing new antiviral agents for influenza treatment: what does the future hold?

Antiviral agents for the treatment of influenza are urgently needed to circumvent the limitations of current drugs in several critical areas: high frequencies of resistance to M2 inhibitors among currently circulating strains and variable frequencies of resistance to oseltamivir among A(H1N1) strains, limited efficacy of treatment and treatment-emergent antiviral resistance in cases of avian influenza A(H5N1) illness in humans, and lack of parenteral agents for seriously ill patients. Two neuraminidase inhibitors (NAIs), zanamivir and peramivir, have undergone or are undergoing clinical trials for use by intravenous or intramuscular administration, and one long-acting NAI, designated CS-8958, is under study for use by inhalation. Advances in understanding the mechanisms involved in influenza virus replication have revealed a number of potential targets that might be exploited in the development of new agents. Among these agents are T-705, a polymerase inhibitor, and DAS181, an attachment inhibitor. Combination therapy with currently available agents is supported by data from animal models but has received limited clinical study to date.

[1]  E. De Clercq,et al.  Antiviral agents active against influenza A viruses , 2006, Nature reviews. Drug discovery.

[2]  A. Palamara,et al.  Efficacy of combination therapy with amantadine, thymosin alpha 1 and alpha/beta interferon in mice infected with influenza A virus. , 1996, International journal of immunopharmacology.

[3]  A. Galabov,et al.  Rimantadine and Oseltamivir Demonstrate Synergistic Combination Effect in an Experimental Infection with Type a (H3N2) Influenza Virus in Mice , 2006, Antiviral chemistry & chemotherapy.

[4]  R. Webster,et al.  Amantadine-Oseltamivir Combination therapy for H5N1 Influenza Virus Infection in Mice , 2006, Antiviral therapy.

[5]  Keiji Fukuda,et al.  WHO Rapid Advice Guidelines for pharmacological management of sporadic human infection with avian influenza A (H5N1) virus , 2006, The Lancet Infectious Diseases.

[6]  Y. Guan,et al.  Treatment with convalescent plasma for influenza A (H5N1) infection. , 2007, The New England journal of medicine.

[7]  M. Kiso,et al.  Lower clinical effectiveness of oseltamivir against influenza B contrasted with influenza A infection in children. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  F. Hayden,et al.  Recovery of drug-resistant influenza A virus during therapeutic use of rimantadine , 1991, Antimicrobial Agents and Chemotherapy.

[9]  M. Bray,et al.  Current and future antiviral therapy of severe seasonal and avian influenza , 2008, Antiviral Research.

[10]  C. Pannuti,et al.  Use of Oseltamivir to control influenza complications after bone marrow transplantation , 2004, Bone Marrow Transplantation.

[11]  P. Ward,et al.  Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. , 2005, The Journal of antimicrobial chemotherapy.

[12]  S. Tiu,et al.  Blood Glucose Overestimation Using Hemoglucostix in a Diabetic Patient on Icodextrin-based Peritoneal Dialysis , 2004 .

[13]  Nicholas J. White,et al.  Oseltamivir Is Adequately Absorbed Following Nasogastric Administration to Adult Patients with Severe H5N1 Influenza , 2008, PloS one.

[14]  F. Hayden,et al.  Sialidase Fusion Protein as a Novel Broad-Spectrum Inhibitor of Influenza Virus Infection , 2006, Antimicrobial Agents and Chemotherapy.

[15]  N. Cox,et al.  Common emergence of amantadine- and rimantadine-resistant influenza A viruses in symptomatic immunocompromised adults. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  J. Farrar,et al.  Prophylactic and Therapeutic Efficacy of Human Monoclonal Antibodies against H5N1 Influenza , 2007, PLoS medicine.

[17]  H. Goto,et al.  High frequency of resistant viruses harboring different mutations in amantadine-treated children with influenza. , 2003, The Journal of infectious diseases.

[18]  H. Hsieh,et al.  Strategies of development of antiviral agents directed against influenza virus replication. , 2007, Current pharmaceutical design.

[19]  J. Manuguerra,et al.  Failure of Zanamivir Therapy for Pneumonia in a Bone-Marrow Transplant Recipient Infected by a Zanamivir-Sensitive Influenza a (H1N1) Virus , 2007, Antiviral therapy.

[20]  N. Cox,et al.  Prevention and Control of Influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). , 2006, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[21]  M. Boeckh,et al.  Safety and tolerability of oseltamivir prophylaxis in hematopoietic stem cell transplant recipients: a retrospective case-control study. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  P. Chan,et al.  Oseltamivir prophylaxis during the influenza season in a paediatric cancer centre: prospective observational study. , 2004, Hong Kong medical journal = Xianggang yi xue za zhi.

[23]  M. Keating,et al.  Respiratory Viral Infections in Adults With Hematologic Malignancies and Human Stem Cell Transplantation Recipients: A Retrospective Study at a Major Cancer Center , 2006, Medicine.

[24]  F. Hayden,et al.  Intravenous ribavirin by constant infusion for serious influenza and parainfluenzavirus infection. , 1996, Antiviral therapy.

[25]  F. Hayden,et al.  Update on avian influenza A (H5N1) virus infection in humans. , 2008, The New England journal of medicine.

[26]  A. Palamara,et al.  Efficacy of combination therapy with amantadine, thymosin α1 and α/β interferon in mice infected with influenza a virus , 1996 .

[27]  Yi Guan,et al.  Oseltamivir resistance during treatment of influenza A (H5N1) infection. , 2005, The New England journal of medicine.

[28]  H. Narita,et al.  In Vitro and In Vivo Activities of Anti-Influenza Virus Compound T-705 , 2002, Antimicrobial Agents and Chemotherapy.

[29]  L. Aschenbrenner,et al.  DAS181, a novel sialidase fusion protein, protects mice from lethal avian influenza H5N1 virus infection. , 2007, The Journal of infectious diseases.

[30]  S. Bantia,et al.  Anti-influenza virus activity of peramivir in mice with single intramuscular injection. , 2006, Antiviral research.

[31]  J. Farrar,et al.  The Southeast Asian Influenza Clinical Research Network: development and challenges for a new multilateral research endeavor. , 2008, Antiviral research.

[32]  A. Monto,et al.  Prevention and treatment of influenza in high-risk groups: children, pregnant women, immunocompromised hosts, and nursing home residents. , 2006, The Journal of infectious diseases.

[33]  M. Kiso,et al.  Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors. , 2007, JAMA.

[34]  Xiyan Xu,et al.  Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern , 2005, The Lancet.

[35]  Alan Bye,et al.  Pharmacokinetics of Zanamivir After Intravenous, Oral, Inhaled or Intranasal Administration to Healthy Volunteers , 1999, Clinical pharmacokinetics.

[36]  F. Hayden,et al.  Oral ribavirin treatment of influenza A and B , 1987, Antimicrobial Agents and Chemotherapy.

[37]  G. A. Galegov,et al.  Combined Inhibition of Influenza Virus Reproduction in Cell Culture using Interferon and Amantadine , 1968, Nature.

[38]  Vasiliy P. Mishin,et al.  Susceptibilities of Antiviral-Resistant Influenza Viruses to Novel Neuraminidase Inhibitors , 2005, Antimicrobial Agents and Chemotherapy.

[39]  F. Hayden,et al.  Emergence and apparent transmission of rimantadine-resistant influenza A virus in families. , 1989, The New England journal of medicine.

[40]  J. Raboud,et al.  Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[41]  F. Hayden,et al.  Safety and Efficacy of Intravenous Zanamivir in Preventing Experimental Human Influenza A Virus Infection , 1999, Antimicrobial Agents and Chemotherapy.

[42]  D. Smee,et al.  Efficacy of Orally Administered T-705 on Lethal Avian Influenza A (H5N1) Virus Infections in Mice , 2006, Antimicrobial Agents and Chemotherapy.

[43]  Yoshihiro Kawaoka,et al.  oseltamivir: descriptive study , 2022 .

[44]  F. Hayden,et al.  Combined interferon-alpha 2, rimantadine hydrochloride, and ribavirin inhibition of influenza virus replication in vitro , 1984, Antimicrobial Agents and Chemotherapy.

[45]  F. Hayden,et al.  Antivirals for influenza: historical perspectives and lessons learned. , 2006, Antiviral research.

[46]  N. Roberts,et al.  Treatment of influenza with neuraminidase inhibitors: virological implications. , 2001, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[47]  Nobuhiko Nomura,et al.  Mechanism of Action of T-705 against Influenza Virus , 2005, Antimicrobial Agents and Chemotherapy.

[48]  F. Hayden,et al.  Evaluation of Neuraminidase Enzyme Assays Using Different Substrates To Measure Susceptibility of Influenza Virus Clinical Isolates to Neuraminidase Inhibitors: Report of the Neuraminidase Inhibitor Susceptibility Network , 2003, Journal of Clinical Microbiology.

[49]  M. Boeckh,et al.  Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[50]  Monitoring of neuraminidase inhibitor resistance among clinical influenza virus isolates in Japan during the 2003-2006 influenza seasons. , 2007, Releve epidemiologique hebdomadaire.

[51]  R. Webster,et al.  Oseltamivir-Ribavirin Combination Therapy for Highly Pathogenic H5N1 Influenza Virus Infection in Mice , 2007, Antimicrobial Agents and Chemotherapy.

[52]  R. Sidwell,et al.  In vitro and in vivo sensitivity of a non-mouse-adapted influenza A (Beijing) virus infection to amantadine and ribavirin. , 1995, Chemotherapy.

[53]  J. Sung,et al.  Antiviral treatment for patients hospitalized with severe influenza infection may affect clinical outcomes. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[54]  F. Hayden,et al.  Safety and Efficacy of Nebulized Zanamivir in Hospitalized Patients with Serious Influenza , 2002, Antiviral therapy.

[55]  Angus Nicoll,et al.  Avian influenza A (H5N1) infection in humans. , 2005, The New England journal of medicine.

[56]  F. Hayden,et al.  John F. Enders lecture 2006: antivirals for influenza. , 2007, The Journal of infectious diseases.

[57]  A. Osterhaus,et al.  Evaluation of intravenous zanamivir against experimental influenza A (H5N1) virus infection in cynomolgus macaques. , 2008, Antiviral research.

[58]  C. Hall,et al.  Children with influenza A infection: treatment with rimantadine. , 1987, Pediatrics.

[59]  S. Kashiwagi,et al.  A comparison of the effectiveness of oseltamivir for the treatment of influenza A and influenza B: a Japanese multicenter study of the 2003-2004 and 2004-2005 influenza seasons. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[60]  F. Hayden,et al.  Recovery of drug-resistant influenza virus from immunocompromised patients: a case series. , 2006, The Journal of infectious diseases.

[61]  N. Dziuba,et al.  Injectable peramivir mitigates disease and promotes survival in ferrets and mice infected with the highly virulent influenza virus, A/Vietnam/1203/04 (H5N1). , 2008, Virology.

[62]  N. Cox,et al.  Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. , 2007, The Journal of infectious diseases.

[63]  J. Sung,et al.  Factors Associated with Early Hospital Discharge of Adult Influenza Patients , 2007, Antiviral therapy.

[64]  H. T. Jones,et al.  Potent and Long-Acting Dimeric Inhibitors of Influenza Virus Neuraminidase Are Effective at a Once-Weekly Dosing Regimen , 2004, Antimicrobial Agents and Chemotherapy.

[65]  Larisa V. Gubareva,et al.  Comparison of the Activities of Zanamivir, Oseltamivir, and RWJ-270201 against Clinical Isolates of Influenza Virus and Neuraminidase Inhibitor-Resistant Variants , 2001, Antimicrobial Agents and Chemotherapy.

[66]  S. Kashiwagi,et al.  Factors influencing the effectiveness of oseltamivir and amantadine for the treatment of influenza: a multicenter study from Japan of the 2002-2003 influenza season. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[67]  P. Ward,et al.  Oral oseltamivir treatment of influenza in children , 2001, The Pediatric infectious disease journal.

[68]  L. Kong,et al.  Successful treatment of avian influenza with convalescent plasma. , 2006, Hong Kong medical journal = Xianggang yi xue za zhi.